Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2025 01:00 ET | Source: VERAXA Biotech GmbH

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today the...
May 05, 2025 01:00 ET | Source: VERAXA Biotech GmbH

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp....
April 23, 2025 01:09 ET | Source: VERAXA Biotech GmbH

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE")...
August 14, 2024 07:07 ET | Source: Panavance Therapeutics Inc.

Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine

Misetionamide demonstrated significant single agent activity and synergy with either PARP inhibitors (PARPi) or bevacizumab in ovarian cancer preclinical studiesProfound effects on tumor metabolism,...
January 21, 2022 04:29 ET | Source: Research and Markets

Worldwide Filgrastim Industry to 2027 - An Increase in the Aging Population is Driving Growth

Dublin, Jan. 21, 2022 (GLOBE NEWSWIRE) -- The "Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027"...